HealthEquity, Inc. (NASDAQ:HQY) Holdings Lowered by Moody Aldrich Partners LLC

Moody Aldrich Partners LLC trimmed its stake in shares of HealthEquity, Inc. (NASDAQ:HQY) by 2.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 56,895 shares of the company’s stock after selling 1,151 shares during the period. Moody Aldrich Partners LLC owned about 0.07% of HealthEquity worth $4,657,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of HQY. International Assets Investment Management LLC acquired a new position in HealthEquity during the second quarter valued at $35,000. Paladin Wealth LLC acquired a new position in HealthEquity in the 3rd quarter worth about $39,000. Fidelis Capital Partners LLC acquired a new position in HealthEquity in the 1st quarter worth about $42,000. GAMMA Investing LLC increased its position in HealthEquity by 114.8% in the 2nd quarter. GAMMA Investing LLC now owns 595 shares of the company’s stock worth $51,000 after purchasing an additional 318 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in HealthEquity in the 2nd quarter worth about $73,000. 99.55% of the stock is owned by hedge funds and other institutional investors.

HealthEquity Stock Performance

HQY stock traded up $0.17 during midday trading on Thursday, hitting $87.78. The stock had a trading volume of 29,984 shares, compared to its average volume of 609,156. The firm has a market capitalization of $7.64 billion, a price-to-earnings ratio of 95.23, a P/E/G ratio of 1.31 and a beta of 0.52. HealthEquity, Inc. has a 52 week low of $61.81 and a 52 week high of $89.23. The stock has a 50-day simple moving average of $79.77 and a 200 day simple moving average of $79.62. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51.

HealthEquity (NASDAQ:HQY) last announced its quarterly earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.50 by $0.16. The firm had revenue of $299.93 million for the quarter, compared to analysts’ expectations of $284.48 million. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. As a group, equities research analysts anticipate that HealthEquity, Inc. will post 2.27 earnings per share for the current year.

Analyst Ratings Changes

HQY has been the topic of several research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $92.00 target price on shares of HealthEquity in a research report on Wednesday, September 4th. Bank of America decreased their price target on HealthEquity from $105.00 to $100.00 and set a “buy” rating for the company in a research note on Wednesday, September 4th. JMP Securities reiterated a “market outperform” rating and set a $105.00 price target on shares of HealthEquity in a research note on Wednesday, September 4th. Deutsche Bank Aktiengesellschaft increased their target price on HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. Finally, Barrington Research restated an “outperform” rating and set a $105.00 target price on shares of HealthEquity in a research note on Friday, September 20th. Twelve research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $103.83.

Insider Buying and Selling at HealthEquity

In other news, Director Robert W. Selander sold 8,250 shares of the firm’s stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total value of $684,585.00. Following the completion of the sale, the director now directly owns 54,719 shares in the company, valued at approximately $4,540,582.62. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, Director Frank Corvino sold 1,247 shares of the firm’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $80.26, for a total value of $100,084.22. Following the completion of the sale, the director now directly owns 4,823 shares in the company, valued at approximately $387,093.98. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Robert W. Selander sold 8,250 shares of HealthEquity stock in a transaction dated Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total value of $684,585.00. Following the completion of the sale, the director now owns 54,719 shares of the company’s stock, valued at approximately $4,540,582.62. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 2.20% of the company’s stock.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.